EA
KRTX

Emerald Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Emerald Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-610
Closed -$193K – 266
2023
Q4 		$193K Sell
610
-26,814
-98% -$5.21M 0.01% 219
2023
Q3 		$4.64M Sell
27,424
-232
-0.8% -$43.6K 0.22% 111
2023
Q2 		$6M Sell
27,656
-49,514
-64% -$10.6M 0.26% 107
2023
Q1 		$14M Sell
77,170
-23,760
-24% -$4.54M 0.67% 69
2022
Q4 		$19.8M Sell
100,930
-18,898
-16% -$4.05M 0.96% 43
2022
Q3 		$27M Sell
119,828
-700
-0.6% -$142K 1.39% 13
2022
Q2 		$15.2M Sell
120,528
-134,028
-53% -$15.4M 0.78% 51
2022
Q1 		$32.3M Buy
254,556
+23,684
+10% +$2.67M 1.23% 24
2021
Q4 		$30.2M Buy
230,872
+18,850
+9% +$2.44M 1.12% 28
2021
Q3 		$25.9M Buy
212,022
+7,608
+4% +$878K 0.94% 41
2021
Q2 		$23.3M Buy
204,414
+31,290
+18% +$3.66M 0.85% 42
2021
Q1 		$20.8M Buy
+173,124
New +$19.6M 0.75% 59

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Emerald Advisers's KRTX Position: Q1 2024 in Review

Emerald Advisers sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 610 shares — an estimated $193K sold.

Emerald Advisers first reported a position in KRTX in Q1 2021 and held it in 12 quarters. The position peaked at $32.3M in Q1 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Emerald Advisers reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Emerald Advisers sold 610 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $193K.
  • Emerald Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • Emerald Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $32.3M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Emerald Advisers's 13F filing for Q1 2024, filed 8 May 2024.